Inovio Pharmaceuticals, Inc.
INO
$1.64
-$0.05-2.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 20.80% | 4.24% | 27.85% | 22.78% | 20.62% |
| Total Depreciation and Amortization | -4.50% | 19.03% | 8.25% | 0.09% | -10.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.12% | 502.20% | -111.88% | -112.46% | -84.51% |
| Change in Net Operating Assets | -245.92% | -51.81% | 3.47% | 47.67% | 74.02% |
| Cash from Operations | 14.84% | 19.66% | 15.63% | 12.25% | 16.31% |
| Capital Expenditure | 41.44% | 67.55% | 81.49% | -760.00% | -52.04% |
| Sale of Property, Plant, and Equipment | -- | -60.01% | -60.01% | -60.01% | -99.05% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -86.29% | -45.56% | -23.03% | -48.01% | 28.29% |
| Cash from Investing | -86.51% | -45.46% | -22.70% | -48.45% | 19.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 100.00% | 100.00% | -- |
| Issuance of Common Stock | 0.20% | -11.01% | -40.36% | 199.23% | 560.97% |
| Repurchase of Common Stock | 73.66% | 73.66% | 72.78% | -48.33% | 9.86% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -47.26% | 104.69% | -0.51% | -- | -- |
| Cash from Financing | 3.06% | 127.82% | 27.24% | 1,174.43% | 930.52% |
| Foreign Exchange rate Adjustments | -- | -100.00% | -100.00% | -100.00% | 930.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -141.82% | 416.12% | 45.19% | 335.21% | 260.85% |